Craig Parker
Chief Executive Officer bij SURROZEN, INC.
Vermogen: 23 157 $ op 31-03-2024
Profiel
Craig C.
Parker was the founder of Vega Therapeutics, Inc. (founded in 2009) where he served as the Chief Executive Officer from 2009 to 2011.
He currently holds the position of President, Chief Executive Officer & Director at Surrozen Operating, Inc. (since 2018), Surrozen, Inc. (since 2018), and Chairman-Leadership Council at the University of Michigan (since 2005).
In his former roles, Mr. Parker worked as a Managing Director at Lehman Brothers, Inc., Director at Gryphon Therapeutics, Inc., Independent Director at vTv Therapeutics, Inc. (from 2015 to 2019), Senior Vice President & General Manager at Immunex Corp.
(from 1999 to 2001), Senior VP-Strategy & Corporate Development at Human Genome Sciences, Inc. (from 2011 to 2012), EVP-Corporate Development & Scientific Affairs at Geron Corp.
(from 2012 to 2014), Chief Financial Officer at Proteolix, Inc. (from 2012 to 2013), and Senior VP-Corporate Development at Jazz Pharmaceuticals Plc (from 2014 to 2018).
Mr. Parker's education includes an undergraduate degree from The University of Chicago, an MBA from the University of Michigan, and an MBA from the Stephen M.
Ross School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SURROZEN INC
0.07% | 04-04-2024 | 1 474 ( 0.07% ) | 23 157 $ | 31-03-2024 |
Actieve functies van Craig Parker
| Bedrijven | Functie | Begin |
|---|---|---|
| SURROZEN, INC. | Chief Executive Officer | 01-03-2018 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 04-04-2018 |
| University of Michigan | Chairman | - |
Eerdere bekende functies van Craig Parker
| Bedrijven | Functie | Einde |
|---|---|---|
| VTV THERAPEUTICS INC. | Director/Board Member | 01-02-2019 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01-03-2018 |
| GERON CORPORATION | Chief Tech/Sci/R&D Officer | 31-07-2014 |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Director of Finance/CFO | 26-11-2013 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 03-08-2012 |
Opleiding van Craig Parker
| The University of Chicago | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
| Stephen M. Ross School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GERON CORPORATION | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| VTV THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Gryphon Therapeutics, Inc.
 Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
| Surrozen, Inc. | |
| Vega Therapeutics, Inc. |
